Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptional profiling of patient-derived xenograft models of myxoid liposarcoma either responsive or resistant to trabectedin treatment.

ABSTRACT: Transcriptional profiling of patient-derived xenograft models of myxoid liposarcoma with either FUS-CHOP type I, named as ML017, or FUS-CHOP type III, named as ML006. Both ML017 and ML006 are responsive to trabectedin treatment, while model ML017/ET has aquired resistance to the drug. Samples are either under untreated conditions, or treated either with trabectedin or pioglitazone or both.

ORGANISM(S): Homo sapiens

SUBMITTER: Laura Mannarino

PROVIDER: E-MTAB-8632 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin.

Bello Ezia E Brich Silvia S Craparotta Ilaria I Mannarino Laura L Ballabio Sara S Gatta Raffaella R Marchini Sergio S Carrassa Laura L Matteo Cristina C Sanfilippo Roberta R Gronchi Alessandro A Casali Paolo Giovanni PG Pilotti Silvana S D'Incalci Maurizio M Frapolli Roberta R

British journal of cancer 20190814 6

<h4>Background</h4>Myxoid liposarcoma is a histological subtype of liposarcoma particularly sensitive to trabectedin. In clinical use this drug does not cause cumulative toxicity, allowing prolonged treatment, generally until disease progression. No other effective therapies are available for trabectedin-resistant patients.<h4>Methods</h4>Through repeated in vivo treatment in athymic nude mice, we have obtained a patient-derived xenograft with acquired resistance to trabectedin.<h4>Results</h4>A ...[more]

PMID: 31409911

Publication: 1/2

Similar Datasets

Comparison Between Gene Expression Profiles of Sensitive and Resistant Trabectedin Liposarcoma Cell Lines

Project description:Gene expression profiles of 402-91 FUS-CHOP type I cells have been compared to 402-91/ET cells made resistant to Trabectedin

2010-07-13 | GSE20350 | GEO

Transcriptional profiling of human myxoid liposarcoma xenografts treated with trabectedin

Project description:To elucidate the mechanisms behind the high sensitivity of myxoid/round cell liposarcoma (MRCL) to trabectedin and the suggested selectivity for specific subtypes we have developed and characterized two MRCL xenografts differing for the breakpoint of the fusion gene FUS- HOP, respectively of type II and III. Transcription profiling experiments were carried out after trabectidin treatment in four separate time points (control, 24h after the first dose, 24h after the third dose, and 15 days after the third dose) for both types of xenografts in order to identify genes and pathways involved with the mechanisms of action of trabectedin in MRCL.

2013-12-10 | E-MTAB-1809 | biostudies-arrayexpress

Comparison Between Gene Expression Profiles of Sensitive and Resistant Trabectedin Liposarcoma Cell Lines

Project description:Gene expression profiles of 402-91 FUS-CHOP type I cells have been compared to 402-91/ET cells made resistant to Trabectedin Experiments were performed on purified RNA from independent batches of 402-91 and 402-91/ET cells without drug treatment.

2010-07-13 | E-GEOD-20350 | biostudies-arrayexpress

Whole transcriptome profiling by microarray of monocytes stimulated with LPS and treated with trabectedin, lurbinectedin or doxorubicin

Project description:In order to assess the potential difference on the effect of lurbinectedin on monocytes compared to trabectedin, which has a selective killing effect (Germano et al., 2013), we performed a whole transcriptome assay on monocytes from healthy donors stimulated with LPS and with either trabectedin or lurbinectedin. Doxorubicin, an unrelated drug, was used as an internal control.

2018-01-15 | E-MTAB-5366 | biostudies-arrayexpress

miRNA profiling of the MV4-11 cell line treated with trabectidin or azacitidin

Project description:In order to study the effects of trabectedin in chronic myelomonocytic leukemia and in juvenile myelomonocytic leukemia, we performed whole genome transcriptional profiling of a model cell line treated under either the reference drug for CMML / JMML (Azacitidine) or trabectedin.

2017-04-30 | E-MTAB-2979 | biostudies-arrayexpress

Transcriptional profiling of the MV4-11 cell line treated with trabectidin or azacitidin

2016-12-14 | E-MTAB-2978 | biostudies-arrayexpress

TRAIL and taurolidine enhance the anticancer activity of doxorubicin, trabectedin and mafosfamide in human fibrosarcoma cells.

Project description:Microarray analysis revealed differential gene expression patterns of HT1080 cells treated with various chemical compounds alone and in combination (trabectedin, doxorubicin, mafosfamide, TRAIL, taurolidine) Microarray analysis of HT1080 cells treated with various chemical compounds alone and in combination (trabectedin, doxorubicin, mafosfamide, TRAIL, taurolidine)

2011-09-30 | E-GEOD-32441 | biostudies-arrayexpress

PARP1 expression drives the synergy between trabectedin and PARP1 inhibitors

Project description:Trabectedin is a DNA-damaging agent with a peculiar mechanism of action; it traps the DNA repair machinery leading to DNA single- and double-strand breaks, particularly in BRCA1/2-deficient tumors. We hypothesized that trabectedin-induced DNA damage might activate PARP1 (a DNA-repair machinery key player), and consequently, PARP1 inhibition would perpetuate trabectedin-induced DNA damage. In several tumor histotypes, we demonstrated a different degree of synergism between trabectedin and PARP1 inhibitors (PARP1-Is). Independent of BRCA1/2 status, PARP1 expression dictated the degree of synergism. Namely, silenced PARP1 reduced trabectedin-PARP1-Is synergism, whereas overexpressed PARP1 increased combination efficacy. High-PARP1 expression and specific gene signatures associated with DNA damage response and repair (DDR-R) were predictive of trabectedin+PARP1-I synergy. These findings pave the way for the clinical development of this novel combination therapy, as well as evaluation of PARP1 expression and DDR-R signatures in tumor samples as predictive biomarkers of response

2017-06-12 | GSE77175 | GEO

PARP1 expression predicts and determines synergy between PARP1 inhibitors and trabectedin.

2017-06-12 | GSE76981 | GEO

Microarray gene expression profiling of a fibrosarcoma GPNMB-induced cell line MCA-1-GPNMB at basal condition and in the form of spheroids

Project description:The expression of the soluble protein GPNMB (glycoprotein non-metastatic melanoma protein B) induces an aggressive behavior of tumor cells by promoting proliferation and distant spread. The main molecular feature is the over expression of interleukin Il-33. The gene profile of MCA-1-GPNMB and MCA-1-GPNMB-spheroid cell line was assessed against MCA-1-Mock.

2020-07-30 | E-MTAB-8082 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data